These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 27196395)

  • 1. Disparate rates of acute rejection and donor-specific antibodies among high-immunologic risk renal transplant subgroups receiving antithymocyte globulin induction.
    Patel SJ; Suki WN; Loucks-DeVos J; Graviss EA; Nguyen DT; Knight RJ; Kuten SA; Moore LW; Teeter LD; Gaber LW; Gaber AO
    Transpl Int; 2016 Aug; 29(8):897-908. PubMed ID: 27196395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphocyte-depleting induction therapy lowers the risk of acute rejection in African American pediatric kidney transplant recipients.
    Crowson CN; Reed RD; Shelton BA; MacLennan PA; Locke JE
    Pediatr Transplant; 2017 Feb; 21(1):. PubMed ID: 27699934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithymocyte globulin is associated with a lower incidence of de novo donor-specific antibodies in moderately sensitized renal transplant recipients.
    Brokhof MM; Sollinger HW; Hager DR; Muth BL; Pirsch JD; Fernandez LA; Bellingham JM; Mezrich JD; Foley DP; D'Alessandro AM; Odorico JS; Mohamed MA; Vidyasagar V; Ellis TM; Kaufman DB; Djamali A
    Transplantation; 2014 Mar; 97(6):612-7. PubMed ID: 24531846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose rabbit antithymocyte globulin versus basiliximab induction therapy in low-risk renal transplant recipients: 8-year follow-up.
    Laftavi MR; Alnimri M; Weber-Shrikant E; Kohli R; Said M; Patel S; Pankewycz O
    Transplant Proc; 2011 Mar; 43(2):458-61. PubMed ID: 21440733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Antithymocyte Globulin, Basiliximab, and Induction-Free Treatment in Living Donor Kidney Transplant Recipients on Tacrolimus-Based Immunosuppression.
    Sonmez O; Ozcan SG; Karaca C; Atli Z; Dincer MT; Trabulus S; Seyahi N
    Exp Clin Transplant; 2024 Apr; 22(4):270-276. PubMed ID: 38742317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
    Lü TM; Yang SL; Wu WZ; Tan JM
    Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between spousal donor transplantation treated with anti-thymocyte globulin induction therapy and, living related donor transplantation treated with standard immunosuppression.
    Demir E; Paydas S; Erken U
    Saudi J Kidney Dis Transpl; 2014 May; 25(3):520-3. PubMed ID: 24821146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
    Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
    Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppression withdrawal in living-donor renal transplant recipients following induction with antithymocyte globulin and rituximab: Results of a prospective clinical trial.
    Markmann JF; Burrell BE; Bromberg JS; Hartono C; Kaufman DB; Possselt AM; Naji A; Bridges ND; Breeden C; Kanaparthi S; Pardo J; Kopetskie H; Mason K; Lim N; Chandran S
    Am J Transplant; 2024 Jul; 24(7):1193-1204. PubMed ID: 38467375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The risk of acute rejection and the influence of induction agents in lower-risk African American kidney transplant recipients receiving modern immunosuppression.
    Gralla J; Le CN; Cooper JE; Wiseman AC
    Clin Transplant; 2014 Mar; 28(3):292-8. PubMed ID: 24476453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Racial differences in incident de novo donor-specific anti-HLA antibody among primary renal allograft recipients: results from a single center cohort study.
    Everly MJ; Briley KP; Haisch CE; Dieplinger G; Bolin P; Kendrick SA; Morgan C; Maldonado AQ; Rebellato LM
    Transpl Int; 2017 Jun; 30(6):566-578. PubMed ID: 28211192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-thymocyte globulin versus basiliximab induction in renal transplant recipients: Long-term outcome.
    Kesiraju S; Paritala P; Rao Ch UM; Athmakuri SM; Reddy VS; Sahariah S
    Saudi J Kidney Dis Transpl; 2014 Jan; 25(1):9-15. PubMed ID: 24434376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction immunosuppression strategies and outcomes post-lung transplant: A single center experience.
    Narula T; Alvarez F; Abdelmoneim Y; Erasmus D; Li Z; Elrefaei M
    Transpl Immunol; 2024 Aug; 85():102081. PubMed ID: 38986916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of antibody induction on transplant outcomes in human leukocyte antigen zero-mismatch deceased donor kidney recipients.
    Kuo HT; Huang E; Emami S; Pham PT; Wilkinson AH; Danovitch GM; Bunnapradist S
    Transplantation; 2012 Mar; 93(5):493-502. PubMed ID: 22306574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating safety and efficacy of rabbit antithymocyte globulin induction in elderly kidney transplant recipients.
    Khanmoradi K; Knorr JP; Feyssa EL; Parsikia A; Jawa P; Dinh DB; Campos S; Zaki RF; Ortiz JA
    Exp Clin Transplant; 2013 Jun; 11(3):222-8. PubMed ID: 23432665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early immunosuppression treatment correlates with later de novo donor-specific antibody development after kidney and pancreas transplantation.
    Pelletier RP; Rajab AA; Diez A; DiPaola NR; Bumgardner GL; Elkhammas EA; Henry ML
    Clin Transplant; 2015 Dec; 29(12):1119-27. PubMed ID: 26382932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rabbit antithymocyte induction and dosing in deceased donor renal transplant recipients over 60 yr of age.
    Patel SJ; Knight RJ; Suki WN; Abdellatif A; Duhart BT; Krauss AG; Mannan S; Nezakatgoo N; Osama Gaber A
    Clin Transplant; 2011; 25(3):E250-6. PubMed ID: 21231963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppression regimen and the risk of acute rejection in HIV-infected kidney transplant recipients.
    Locke JE; James NT; Mannon RB; Mehta SG; Pappas PG; Baddley JW; Desai NM; Montgomery RA; Segev DL
    Transplantation; 2014 Feb; 97(4):446-50. PubMed ID: 24162248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and economic analysis of short-course versus standard-course antithymocyte globulin (rabbit) induction therapy in deceased-donor renal transplant recipients.
    Marfo K; Akalin E; Wang C; Lu A
    Am J Health Syst Pharm; 2011 Dec; 68(23):2276-82. PubMed ID: 22095818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction therapy with basiliximab versus Thymoglobulin in African-American kidney transplant recipients.
    Haririan A; Morawski K; Sillix DH; El-Amm JM; Garnick J; West MS; Granger DK; Migdal SD; Gruber SA
    Transplantation; 2005 Mar; 79(6):716-21. PubMed ID: 15785379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.